Technical Analysis for BBIO - BridgeBio Pharma, Inc.

Grade Last Price % Change Price Change
grade B 32.16 -5.19% -1.76
BBIO closed up 10.99 percent on Wednesday, December 4, 2019, on 1.14 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical BBIO trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish -5.19%
180 Bullish Setup Bullish Swing Setup -5.19%
Wide Bands Range Expansion -5.19%
Wide Bands Range Expansion 5.24%
180 Bullish Setup Bullish Swing Setup 3.28%
Multiple of Ten Bullish Other 3.28%
Wide Bands Range Expansion 3.28%
MACD Bearish Signal Line Cross Bearish 10.90%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 10.90%
NR7 Range Contraction 10.90%

Older signals for BBIO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Organ Systems Anatomy Tyrosine Kinase Receptors Protein Kinase Inhibitor Cardiomyopathy Tyrosine Kinase Familial Amyloid Polyneuropathy Hyperplasia Achondroplasia Congenital Adrenal Hyperplasia Fibroblast Growth Factor Receptor Transthyretin TTR Amyloidosis

Is BBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Indicators
Indicator Value
52 Week High 35.67
52 Week Low 17.61
Average Volume 260,518
200-Day Moving Average 0.0
50-Day Moving Average 23.6418
20-Day Moving Average 29.222
10-Day Moving Average 31.462
Average True Range 2.4067
ADX 28.43
+DI 30.3058
-DI 15.8923
Chandelier Exit (Long, 3 ATRs ) 28.4499
Chandelier Exit (Short, 3 ATRs ) 28.8601
Upper Bollinger Band 35.3694
Lower Bollinger Band 23.0746
Percent B (%b) 0.88
BandWidth 42.07378
MACD Line 2.2806
MACD Signal Line 2.267
MACD Histogram 0.0136
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.60
Resistance 3 (R3) 38.13 36.10 37.82
Resistance 2 (R2) 36.10 34.91 36.34 37.56
Resistance 1 (R1) 35.01 34.17 35.56 35.48 37.30
Pivot Point 32.98 32.98 33.25 33.22 32.98
Support 1 (S1) 31.89 31.79 32.44 32.36 30.54
Support 2 (S2) 29.86 31.05 30.10 30.28
Support 3 (S3) 28.77 29.86 30.02
Support 4 (S4) 29.24